[HTML][HTML] Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose

CH Chung, B Mirakhur, E Chan, QT Le… - New England journal …, 2008 - Mass Medical Soc
CH Chung, B Mirakhur, E Chan, QT Le, J Berlin, M Morse, BA Murphy, SM Satinover…
New England journal of medicine, 2008Mass Medical Soc
Background Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the
epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-
cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to
cetuximab has been reported in some areas of the United States. Methods We analyzed
serum samples from four groups of subjects for IgE antibodies against cetuximab:
pretreatment samples from 76 case subjects who had been treated with cetuximab at …
Background
Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States.
Methods
We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston.
Results
Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-α-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain.
Conclusions
In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-α-1,3-galactose.
The New England Journal Of Medicine